What type of study is this?

December 8, 2025Blood

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

View Full Paper

Ask AI

Bookmark

Overall remission rate of 46.5% achieved after inotuzumab ozogamicin treatment prior to CAR-T therapy.
Median time to next treatment was 35 days, indicating manageable patient transitions.
Observational analysis across multiple countries provided insights into clinical characteristics of treated patients.
This suggests that inotuzumab ozogamicin may serve as an effective bridge therapy before CAR-T administration.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis reveals 46.5% overall remission in relapsed B-ALL patients treated with inotuzumab ozogamicin before CAR-T therapy, suggesting its effectiveness as a bridging treatment.

Cite This Study

Martínez‐Cibrián et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236dda4 https://doi.org/10.1182/blood-2025-2369

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis reveals 46.5% overall remission in relapsed B-ALL patients treated with inotuzumab ozogamicin before CAR-T therapy, suggesting its effectiveness as a bridging treatment.

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

Key Points

Discussion

Implication

Cite This Study

INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider